Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

LYATK1 potently inhibits LPS-mediated pro-inflammatory response

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2]; ;  [1];  [1]
  1. Department of Intensive Care Unit, Taixing People"'s Hospital, Taixing, Jiangsu Province, 225400 (China)
  2. Department of Ophthalmology, Nanjing First Hospital, Nanjing Medical University, Nanjing (China)

Lipopolysaccharide (LPS)-primed monocytes/macrophages produce pro-inflammatory cytokines, which could lead to endotoxin shock. TGF-β-activated kinase1 (TAK1) activation is involved in the process. In the current study, we studied the potential effect of a selective TAK1 inhibitor, LYTAK1, on LPS-stimulated response both in vitro and in vivo. We demonstrated that LYTAK1 inhibited LPS-induced mRNA expression and production of several pro-inflammatory cytokines [interleukin 1β (IL-1β), tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6)] in RAW 264.7 macrophages. LYTAK1's activity was almost nullified with TAK1 shRNA-knockdown. Meanwhile, in both primary mouse bone marrow derived macrophages (BMDMs) and human peripheral blood mononuclear cells (PBMCs), LPS-induced pro-inflammatory cytokine production was again attenuated with LYTAK1 co-treatment. Molecularly, LYTAK1 dramatically inhibited LPS-induced TAK1-nuclear factor kappa B (NFκB) and mitogen-activated protein kinase (Erk, Jnk and p38) activation in RAW 264.7 cells, mouse BMDMs and human PBMCs. In vivo, oral administration of LYTAK1 inhibited LPS-induced activation of TAK1-NFκB-p38 in ex-vivo cultured PBMCs, and cytokine production and endotoxin shock in mice. Together, these results demonstrate that LYTAK1 inhibits LPS-induced production of several pro-inflammatory cytokines and endotoxin shock probably through blocking TAK1-regulated signalings. - Highlights: • LYTAK1 inhibits LPS-induced pro-inflammatory cytokine production in RAW 264.7 cells. • The effect by LYTAK1 is more potent than other known TAK1 inhibitors. • LYTAK1 inhibits LPS-induced cytokine production in primary macrophages/monocytes. • LYTAK1 inhibits LPS-induced TAK1-NFκB and MAPK activation in macrophages/monocytes. • LYTAK1 gavage inhibits LPS-induced endotoxin shock and cytokine production in mice.

OSTI ID:
22594204
Journal Information:
Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 1 Vol. 470; ISSN BBRCA9; ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

Thioredoxin-interacting protein-derived peptide (TN13) inhibits LPS-induced inflammation by inhibiting p38 MAPK signaling
Journal Article · Fri Dec 14 23:00:00 EST 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23107886

Caerulin-induced pro-inflammatory response in macrophages requires TRAF3-p38 signaling activation
Journal Article · Thu Dec 14 23:00:00 EST 2017 · Biochemical and Biophysical Research Communications · OSTI ID:22897532

GSK621 activates AMPK signaling to inhibit LPS-induced TNFα production
Journal Article · Thu Nov 17 23:00:00 EST 2016 · Biochemical and Biophysical Research Communications · OSTI ID:22696688